title: Inhibition of in vitro tumor cell growth by RP215 monoclonal antibody and antibodies raised against its anti-idiotype antibodies.
abstract: RP215 monoclonal antibody (Mab) was shown to recognize carbohydrate-associated epitope(s) in the heavy chains of cancer cell-expressed immunoglobulins, designated in general as CA215 pan cancer marker. Growth inhibitions of tumor cells in vitro by RP215 Mab and antibodies against its anti-idiotype (anti-id) antibodies were investigated. Polyclonal rabbit anti-id antibodies and the corresponding rat anti-id Mabs were generated and characterized. Following immunizations in mice, antisera raised against anti-id antibodies were analyzed by typical immunoassays. It was observed that mouse anti-anti-id sera (Ab3) revealed binding affinity and specificity to CA215 that are comparable to those of RP215. Both RP215 and Ab3 were shown to induce apoptosis of cultured cancer cells in vitro by TUNEL and MTT assays. These experimental observations were consistent with that of in vivo tumor growth inhibition by RP215 in previous nude mouse experiments. Therefore, heterologous or homologous anti-id antibodies of RP215 that contain the internal image of its specific epitope in CA215 may serve as effective anti-cancer vaccines for therapeutic treatments of various cancers in humans. The relative stability of RP215-specific carbohydrate-associated epitope was compared to that of human IgG at extreme pH's (<or=2 or >or=12) or following NaIO(4) treatments. The major molecular forms of CA215 were further documented with various enzyme immunoassays and found to have similar secondary structures to those of normal human immunoglobulin G.
authors.affiliation: UBC Center for Reproductive Health, The University of British Columbia, Vancouver, BC, Canada. andr@interchange.ubc.ca
authors.forename: Gregory
authors.initials: G
authors.lastname: Lee
authors.forename: Bixia
authors.initials: B
authors.lastname: Ge
mesh_terms: D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000302:isolation & purification / Q000494:pharmacology*; D000911:Antibodies, Monoclonal / Q000302:isolation & purification / Q000494:pharmacology*; D000915:Antibody Affinity; D000951:Antigens, Neoplasm / Q000276:immunology / Q000378:metabolism*; D017209:Apoptosis / Q000187:drug effects; D019496:Cancer Vaccines; D048708:Cell Growth Processes / Q000187:drug effects; D045744:Cell Line, Tumor; D000939:Epitopes / Q000276:immunology / Q000378:metabolism*; D006801:Humans; D007114:Immunization; D051379:Mice; D008807:Mice, Inbred BALB C; D009369:Neoplasms / Q000276:immunology / Q000628:therapy; D011487:Protein Conformation; D055550:Protein Stability; D011817:Rabbits; D051381:Rats
chemical_list: D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; C541379:CA215 antigen, human; D019496:Cancer Vaccines; D000939:Epitopes
references.citation: Blood. 2001 Aug 15;98(4):1174-81
references.pmid: 11493467
references.citation: Cancer Biol Ther. 2008 Dec;7(12):2007-14
references.pmid: 19158477
references.citation: J Clin Endocrinol Metab. 2008 Aug;93(8):3179-85
references.pmid: 18477660
references.citation: Cancer Res. 2002 Feb 15;62(4):1036-44
references.pmid: 11861379
references.citation: Genes Chromosomes Cancer. 1998 May;22(1):83-6
references.pmid: 9591639
references.citation: World J Gastroenterol. 2007 Apr 28;13(16):2305-11
references.pmid: 17511028
references.citation: Mol Immunol. 2007 Mar;44(9):2221-7
references.pmid: 17174398
references.citation: Cancer Biomark. 2009;5(4):177-88
references.pmid: 19729827
references.citation: Cancer Res. 1995 Dec 1;55(23 Suppl):5978s-5982s
references.pmid: 7493380
references.citation: Cancer Biomark. 2009;5(3):137-42
references.pmid: 19407368
references.citation: FASEB J. 2007 Sep;21(11):2931-8
references.pmid: 17475920
references.citation: Endocr Relat Cancer. 2006 Jun;13(2):641-51
references.pmid: 16728589
references.citation: Cell Signal. 2007 Feb;19(2):419-27
references.pmid: 16979873
references.citation: Oncogene. 2007 May 28;26(25):3594-602
references.pmid: 17530013
references.citation: Cancer Immunol Immunother. 1992;35(1):19-26
references.pmid: 1611619
references.citation: Int J Biochem Cell Biol. 2004 Nov;36(11):2250-7
references.pmid: 15313470
references.citation: Methods Enzymol. 1986;121:652-63
references.pmid: 3088385
references.citation: Nat Rev Cancer. 2008 Feb;8(2):108-20
references.pmid: 18219306
references.citation: Cancer Res. 2003 Oct 1;63(19):6488-95
references.pmid: 14559841
references.citation: Cancer Biol Ther. 2009 Jan;8(2):161-6
references.pmid: 19029818
references.citation: J Reprod Immunol. 2005 Dec;68(1-2):105-20
references.pmid: 16303183
references.citation: J Reprod Immunol. 1988 Aug;13(3):193-209
references.pmid: 3262744
references.citation: Cancer Res. 2006 Apr 15;66(8):3996-4000
references.pmid: 16618718
references.citation: Blood. 1987 Jan;69(1):199-210
references.pmid: 2431729
references.citation: Appl Immunohistochem Mol Morphol. 2008 May;16(3):232-8
references.pmid: 18301247